BioSpace News Archive

Today, Lieutenant Governor Karyn Polito joined Massachusetts Life Sciences Center (MLSC) President and CEO Travis McCready, leaders from the Massachusetts Biomedical Initiatives (MBI), and state and local officials at the site of MBI’s expansion to celebrate construction progress of the redeveloped facility, which will double the operational capacity for the life sciences incubator.

The Sartorius AI Lab (SAIL) conducts research in the use of artificial intelligence in Sartorius platform solutions for the biopharmaceutical industry

CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

Zelluna Immunotherapy announces the appointment of Namir Hassan as chief executive officer.

Dutch life sciences investor Aglaia Oncology Funds, officially launches its ‘Life Sciences Impact Suite’, a groundbreaking tool enabling measurement and reporting of the social impact realized by investments, alongside financial performance.

Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.

Sphingotec reports study data demonstrating that its proprietary renal function biomarker penKid(R) (Proenkephalin) predicts acute kidney injury (AKI), multi-organ failure and mortality in sepsis patients presenting to the emergency department (ED).

CELLINK’s production is completed in-house without middlemen – this unique advantage enables a workflow with high quality assurance and short lead times.